Latest Breaking News On - Action date - Page 4 : comparemela.com

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. announced that new data on VOXZOGO®? in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The.

BioMarin Pharma (BMRN) Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO to Treat Children Aged 4 Months and Older with Achondroplasia

BioMarin Pharma: CHMP Adopts Positive Opinion To Expand Indication For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced the European Medicines Agency s Committee for Medicinal Products for Human Use has adopt.

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

European Commission Approval Decision Expected Q4 2023 Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study  U.S. Food and Drug Administration PDUFA Target Action Date.

U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma